biostudies-literatureUnknown76(9)Wallerstedt SMUniversity of Gothenburg<h4>Purpose</h4>To assess the evidence for decision making, at the health care and the patient levels, regarding the use of gene expression assays to inform chemotherapy decisions in breast cancer patients with intermediate clinical risk of recurrence.<h4>Methods</h4>Systematic literature searches were performed (January 2002-April 2020) in Medline, Embase, PubMed, Cochrane Library, PsycINFO and HTA databases.<h4>Inclusion criteria</h4>patients (P) were individuals with post-surgical breast cancer at intermediate clinical risk of recurrence; intervention (I)/comparison (C) was (i) use of, versus no use of, a gene expression assay and (ii) withholding versus providing chemotherapy; outcomes (O) were overall survival (OS), health-related quality of life (HRQL), and recurrence. Randomised conEuropean journal of clinical pharmacology1199-1211https://www.ebi.ac.uk/biostudies/studies/S-EPMC7419442biostudies-literaturePersonalised medicine and the decision to withhold chemotherapy in early breast cancer with intermediate risk of recurrence - a systematic review and meta-analysis.PMC7419442Wallerstedt SMLinderholm BOlofsson Bagge RNilsson Ek AStrandell AKovacs AfalsePersonalised medicine and the decision to withhold chemotherapy in early breast cancer with intermediate risk of recurrence - a systematic review and meta-analysis.<h4>Purpose</h4>To assess the evidence for decision making, at the health care and the patient levels, regarding the use of gene expression assays to inform chemotherapy decisions in breast cancer patients with intermediate clinical risk of recurrence.<h4>Methods</h4>Systematic literature searches were performed (January 2002-April 2020) in Medline, Embase, PubMed, Cochrane Library, PsycINFO and HTA databases.<h4>Inclusion criteria</h4>patients (P) were individuals with post-surgical breast cancer at intermediate clinical risk of recurrence; intervention (I)/comparison (C) was (i) use of, versus no use of, a gene expression assay and (ii) withholding versus providing chemotherapy; outcomes (O) were overall survival (OS), health-related quality of life (HRQL), and recurrence. Randomised con2020-01-01T00:00:00Z2020 Sep2026-04-30T16:33:56.145Z2026-04-07T16:09:43.263ZS-EPMC74194423250418310.1007/s00228-020-02914-z